AZD-1390

AZD-1390
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 7-Fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one;
CAS Number	2089288-03-7;
PubChem CID	126689157;
IUPHAR/BPS	11277;
ChemSpider	67886355;
UNII	CI43QFE22O;
ChEMBL	ChEMBL4594429;
Chemical and physical data
Formula	C27H32FN5O2
Molar mass	477.584 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C;
	InChI InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3; Key:VQSZIPCGAGVRRP-UHFFFAOYSA-N;

AZD-1390 is an experimental anticancer drug developed by AstraZeneca that inhibits ataxia telangiectasia mutated (ATM).^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Quick Facts Legal status, Identifiers ...

Close

References